NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc.
NRx Pharmaceuticals (NASDAQ:NRXP) has announced key appointments to its Board of Directors. Michael Taylor, with over 25 years of experience in global credit markets, joins as a Board Member and Board Designee of Smith & Sauer, following their recent financing. Taylor's extensive background includes roles as Partner at Adi Dassler International Family Office and Managing Director at Oppenheimer & Co.
Anita Nunes, CEO and Co-Founder of Smith & Sauer, joins as Board Observer and will be appointed to the Board of Directors of HOPE Therapeutics, a wholly owned subsidiary of NRx. Nunes brings over 20 years of experience in transformative growth and has led Smith and Sauer's recent $27 million investment in Hope Therapeutics and NRx Pharmaceuticals. Her background spans artificial intelligence, healthcare, and strategic consulting, with experience at companies like McKesson and Gilead.
NRx Pharmaceuticals (NASDAQ:NRXP) ha annunciato importanti nomine nel suo Consiglio di Amministrazione. Michael Taylor, con oltre 25 anni di esperienza nei mercati del credito globale, entra come Membro del Consiglio e Designato del Consiglio di Smith & Sauer, a seguito del loro recente finanziamento. L'ampio background di Taylor include ruoli come Partner presso Adi Dassler International Family Office e Direttore Generale di Oppenheimer & Co.
Anita Nunes, CEO e Co-fondatrice di Smith & Sauer, entra come Osservatore del Consiglio e sarà nominata nel Consiglio di Amministrazione di HOPE Therapeutics, una controllata interamente posseduta da NRx. Nunes porta con sé oltre 20 anni di esperienza nella crescita trasformativa e ha guidato l'investimento recente di 27 milioni di dollari di Smith e Sauer in Hope Therapeutics e NRx Pharmaceuticals. Il suo background abbraccia intelligenza artificiale, sanità e consulenza strategica, con esperienze in aziende come McKesson e Gilead.
NRx Pharmaceuticals (NASDAQ:NRXP) ha anunciado nombramientos clave en su Junta Directiva. Michael Taylor, con más de 25 años de experiencia en los mercados de crédito globales, se une como Miembro de la Junta y Designado de la Junta de Smith & Sauer, tras su reciente financiamiento. La amplia experiencia de Taylor incluye roles como Socio en Adi Dassler International Family Office y Director General en Oppenheimer & Co.
Anita Nunes, CEO y Co-fundadora de Smith & Sauer, se une como Observadora de la Junta y será nombrada para la Junta Directiva de HOPE Therapeutics, una subsidiaria de propiedad total de NRx. Nunes aporta más de 20 años de experiencia en crecimiento transformador y ha liderado la reciente inversión de 27 millones de dólares de Smith y Sauer en Hope Therapeutics y NRx Pharmaceuticals. Su experiencia abarca inteligencia artificial, atención médica y consultoría estratégica, con experiencia en empresas como McKesson y Gilead.
NRx Pharmaceuticals (NASDAQ:NRXP)는 이사회에 중요한 임명 사항을 발표했습니다. 마이클 테일러는 글로벌 신용 시장에서 25년 이상의 경험을 가진 이사로서 Smith & Sauer의 이사회 구성원으로 합류하였습니다. 테일러는 Adi Dassler International Family Office의 파트너와 Oppenheimer & Co.의 전무이사를 역임한 폭넓은 경력을 가지고 있습니다.
안니타 누네스는 Smith & Sauer의 CEO이자 공동 창립자로 이사회 관찰자로 참여하며, NRx의 100% 자회사인 HOPE Therapeutics의 이사회에 임명될 예정입니다. 누네스는 20년 이상의 변화 성장 경험을 가지고 있으며, Smith와 Sauer가 Hope Therapeutics와 NRx Pharmaceuticals에 2700만 달러를 투자한 최근 프로젝트를 이끌었습니다. 그녀의 배경은 인공지능, 의료 및 전략 컨설팅을 포괄하며, McKesson 및 Gilead와 같은 기업에서 경험을 쌓았습니다.
NRx Pharmaceuticals (NASDAQ:NRXP) a annoncé des nominations clés au sein de son conseil d'administration. Michael Taylor, fort de plus de 25 ans d'expérience sur les marchés du crédit mondial, rejoint en tant que membre du conseil d'administration et désigné par le conseil de Smith & Sauer, à la suite de leur récent financement. Le vaste parcours de Taylor comprend des rôles comme partenaire chez Adi Dassler International Family Office et directeur général chez Oppenheimer & Co.
Anita Nunes, PDG et cofondatrice de Smith & Sauer, rejoint en tant qu'observatrice du conseil et sera nommée au conseil d'administration de HOPE Therapeutics, une filiale entièrement détenue de NRx. Nunes apporte plus de 20 ans d'expérience en croissance transformative et a dirigé le récent investissement de 27 millions de dollars de Smith et Sauer dans Hope Therapeutics et NRx Pharmaceuticals. Son parcours couvre l'intelligence artificielle, la santé et le conseil stratégique, avec des expériences dans des entreprises comme McKesson et Gilead.
NRx Pharmaceuticals (NASDAQ:NRXP) hat wichtige Ernennungen in seinem Vorstand bekannt gegeben. Michael Taylor, der über 25 Jahre Erfahrung in den globalen Kreditmärkten verfügt, tritt als Vorstandsmitglied und Vorstandsbeauftragter von Smith & Sauer bei, nach deren kürzlicher Finanzierung. Taylors umfangreicher Hintergrund umfasst Rollen als Partner bei Adi Dassler International Family Office und als Geschäftsführer bei Oppenheimer & Co.
Anita Nunes, CEO und Mitgründerin von Smith & Sauer, tritt als Beobachterin in den Vorstand ein und wird in den Vorstand von HOPE Therapeutics, einem vollständig im Besitz von NRx befindlichen Tochterunternehmen, berufen. Nunes bringt mehr als 20 Jahre Erfahrung in der transformativem Wachstum mit und hat die kürzliche Investition von 27 Millionen Dollar von Smith und Sauer in Hope Therapeutics und NRx Pharmaceuticals geleitet. Ihr Hintergrund umfasst künstliche Intelligenz, Gesundheitswesen und strategische Beratung und sie hat Erfahrungen bei Unternehmen wie McKesson und Gilead gesammelt.
- Secured $27 million investment from Smith & Sauer
- Addition of experienced financial expert Michael Taylor to Board of Directors
- Strategic appointment of Anita Nunes with healthcare and AI expertise
- None.
Michael Taylor brings over 25 years of experience in global credit markets, with a focus on special situations and capital formation. He has served as Partner at the Adi Dassler International Family Office in
A graduate of the London School of Economics with a Bachelor of Science in Economics and International Relations, Michael has built a reputation for navigating complex financial environments and delivering innovative solutions. These skills will be integral to the growth of the HOPE clinic network. He joins NRx Pharmaceuticals as the Board Designee of Smith & Sauer, LLC, following the recently announced financing.
Anita Nunes, CEO and Co-Founder of Smith & Sauer, LLC, is an accomplished executive with more than 20 years of experience leading transformative growth across industries. She has driven investments in pioneering ventures, including Smith and Sauer's recent
Anita has a strong background in artificial intelligence, where she has led global initiatives to integrate AI-driven solutions, enabling businesses to achieve operational excellence and adapt to dynamic market demands. Her extensive healthcare expertise includes work with industry leaders McKesson and Gilead, where she was instrumental in managing strategic initiatives and fostering innovation.
In addition to her work at Smith & Sauer, Anita is the Founder of Mocktail Nation, a health-conscious beverage brand, and Pluzze Consulting, where she has provided strategic guidance to empower entrepreneurs and investors. Her ability to align financial strategies with impactful outcomes has positioned her as a leader in purpose-driven investments, delivering long-term value to stakeholders and society. She has served on multiple Boards of Directors and is recognized for her extensive expertise in healthcare, technology, and pharmaceuticals.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced initiation of filing a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a development stage healthcare delivery company that intends to develop a best-in-class network of interventional psychiatry clinics to offer ketamine transcranial magnetics stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, Hope Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund the Hope Therapeutics acquisitions, and the Company's ability to spin-off Hope Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-announces-the-appointment-of-michael-taylor-to-its-board-of-directors-and-appointment-of-anita-nunes-as-board-observer-ms-nunes-to-be-appointed-director-of-hope-therapeutics-inc-302351477.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
What is the size of Smith & Sauer's investment in NRXP and Hope Therapeutics?
Who are the new board appointments at NRXP announced in January 2024?
What is Michael Taylor's background and role at NRXP?
What is Anita Nunes' experience and new position at NRXP?
